Dopamine Sensitive ELISA Assay Utilized in Recent Publication

The Eagle Bioscience’s Rituximab mAb-based ELISA was utilized in a recent publication that focused on how rituximab induced cytokine release with high concentrations of serum IP-10 concentrations is associated with infusion reactions. Check out the full text and abstract below.


Monoclonal antibody induced infusion reactions (IRs) can be serious and even fatal. We used clinical data and blood samples from 37 treatment naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) initiating therapy for progressive disease with a single 50 mg dose of intravenous (IV) rituximab at 25 mg/h. Twenty-four (65 %) patients had IRs at a median of 78 min (range 35–128) and rituximab dose of 32 mg (range 15–50). IR risk did not correlate with patient or CLL characteristics, CLL counts or CD20 levels, or serum rituximab or complement concentrations. Thirty-five (95 %) patients had cytokine release response with a ≥ 4-fold increase in serum concentration of ≥ 1 inflammatory cytokine. IRs were associated with significantly higher post-infusion serum concentrations of gamma interferon induced cytokines IP-10, IL-6 and IL-8. IP-10 concentrations increased ≥ 4-fold in all patients with an IR and were above the upper limit of detection (40,000 pg/ml) in 17 (71 %). In contrast, to only three (23 %) patients without an IR had an ≥ 4-fold increase in serum concentrations of IP-10 (highest 22,013 pg/ml). Our data suggest that cytokine release could be initiated by activation of effector cells responsible for clearance of circulating CLL cells with IRs occurring in those with higher levels of gamma interferon induced cytokines. These novel insights could inform future research to better understand and manage IRs and understand the role of cytokines in the control of cytotoxic immune responses to mAb.

Moore, Jeremiah E., et al. “Rituximab Induced Cytokine Release with High Serum IP-10 (CXCL10) Concentrations Is Associated with Infusion Reactions.” Leukemia Research, vol. 129, 2023, p. 107072.

If you have any questions about our Rituximab mAb-based ELISA or our other offerings, please contact us here.